Skip to content

Quality of Life Improvement After TAVI (QualiTAVI-UK Trial)

Quality of Life Improvement After Transcatheter Aortic Valve Implantation (TAVI) in the UK: A Prospective 1-Year Study (QualiTAVI-UK Trial)

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07193004
Acronym
QualiTAVI-UK
Enrollment
100
Registered
2025-09-25
Start date
2025-11-01
Completion date
2027-02-01
Last updated
2025-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental Health, Quality of Life, TAVI, TAVI(Transcatheter Aortic Valve Implantation)

Keywords

Transcatheter aortic valve implantation (TAVI), quality of life, Kansas City Cardiomyopathy Questionnaire, Mini-Montreal Cognitive Assessment (Mini-MoCA), life expectancy, Mental health, Clinical Frailty Scale (CFS)

Brief summary

Transcatheter aortic valve implantation (TAVI) has become an important therapeutic intervention for patients with symptomatic severe aortic stenosis (AS) who are at high surgical risk. While the clinical outcomes of TAVI are well established, there is limited data on the long-term quality of life (QoL) following the procedure. This prospective study will assess QoL in patients undergoing TAVI at Derriford Hospital, University Hospitals Plymouth, UK. Investigators will employ the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) and Mini-Montreal Cognitive Assessment (Mini-MoCA) to evaluate both physical and mental health outcomes, supplemented by an analysis of life expectancy estimated by a multidisciplinary team (MDT). Data will be collected at referral, pre-procedural, 30 days, and 3 months post-TAVI. This will be the first prospective trial focused on QoL improvement after TAVI, as all previous studies have been retrospective in nature. The study aims to provide comprehensive insights into the QoL improvements after TAVI, which will guide future clinical decision-making in this population.

Detailed description

Study Title uality of Life Improvement after Transcatheter Aortic Valve Implantation (TAVI) in the UK: A Prospective 1-Year Study (QualiTAVI-UK trial) Study Design This is a prospective, single-center study that will be conducted over 1 year at Derriford Hospital, University Hospitals Plymouth, UK. Study Participants The study will include all patients undergoing TAVI for severe AS during this period. Eligibility Criteria Inclusion Criteria: Patients who were eligible and accepted for TAVI procedure regardless of the patient's age and informed consent provided by the patient for the TAVI procedure. Exclusion Criteria: Patients who declined enrollment in this research. Planned Sample Size More than 100 patients Follow-up Duration 3 months Planned Study Period 1 year Primary Objective This study aims to address the knowledge gap regarding the impact of TAVI on Quality of Life (QoL) Secondary Objective -

Interventions

BEHAVIORALQuality of Life

Measures - We will use the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) to assess QoL, Mini-Montreal Cognitive Assessment (Mini-MoCA) to assess cognitive function, the Clinical Frailty Scale (CFS) to assess frailty status, and life expectancy estimation by the heart team to categorize patients as having: 1-2 years expected survival or more than 2 years expected survival (This will allow for an analysis of how life expectancy correlates with QoL improvements after TAVI). Assessment Timeline - Patients will be assessed at four key time points: at time of referral (baseline assessment), pre-procedure (to assess impact of delay on the patient), 30 days post-TAVI (early follow-up to assess recovery and improvement in QoL), and 3 months post-TAVI (longer-term follow-up to evaluate sustained QoL changes). At each time point, the KCCQ-12, Mini-MoCA, and Clinical Frailty Scale (CFS) will be administered.

Sponsors

University Hospital Plymouth NHS Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients who were eligible and accepted for TAVI procedure regardless of the patient's age and informed consent provided by the patient for the TAVI procedure.

Exclusion criteria

* Patients who declined enrollment in this research.

Design outcomes

Primary

MeasureTime frameDescription
Improvement of QoL30 days post-TAVI (early follow-up to assess recovery and improvement in QoL), and 3 months post-TAVIThis is defined as improvement in QoL scores from baseline to 3 months post-TAVI. Based on KCCQ-12, a change of 5 points (small but clinically important change), 10 points (moderate-to-large), and 20 points (large-to-very large clinical changes). Based on CFS score, worsened frailty is defined as an increase in CFS score of +4, and improved frailty by a decrease of -2.

Secondary

MeasureTime frameDescription
Correlation between life expectancy and QoL improvements30 days post-TAVI (early follow-up to assess recovery and improvement in QoL), and 3 months post-TAVICorrelation between life expectancy and QoL improvements using regression analysis. Mental health and cognitive function (Mini-MoCA scores), frailty status (CFS), will be explored as potential mediators of QoL outcomes.

Countries

United Kingdom

Contacts

Primary ContactAyman Helal, MD Cardiology
ayman.helal1@nhs.net+447376863806
Backup ContactVenkatesan Suresh, MD Cardiology
vsuresh@nhs.net+447766460037

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026